Sernova Corp. (SVA.TO) TSX

0.19

+0.005(+2.78%)

Updated at October 03 10:52AM

Currency In CAD

Sernova Corp.

Address

The Stiller Centre

London, ON N6G 4X8

United Kingdom of Great Britain and Northern Ireland

Phone

519 858 5184

Sector

Healthcare

Industry

Biotechnology

Employees

17

First IPO Date

April 29, 1999

Key Executives

NameTitlePayYear Born
Mr. Jonathan M. N. Rigby M.B.A., MBAChief Executive Officer & Director693,3971968
Dr. Frank Shannon M.D.Senior Vice President of Clinical Development and Regulatory Affairs335,833N/A
Mr. James T. Parsons CPA-CA, MAccChief Financial Officer467,1821965
Dr. Modestus Obochi M.B.A., Ph.D.Chief Business Officer499,487N/A
Dr. Pericles Calias Ph.D.Chief Development Officer and Head of R&D01968
Ms. Marylyn RigbyChief Communications Officer0N/A
Mr. David BurkeVice President of Investor Relations0N/A

Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.